Xenobe Research Institute
- Assets
- $228.1k
- Revenue
- $61.3k
- Investments
- $0.0
- Employees
- 0
- Location
- San Diego, CA
- Founding
- 10/2005
- Data as of
- 06/2024
- EIN
- 20-1624945
Organization Overview
Xenobe Research Institute is located in San Diego, CA. The organization was established in 2005. According to its NTEE Classification (Z99) the organization is classified as: Unknown, under the broad grouping of Unknown and related organizations. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Xenobe Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2024, Xenobe Research Institute generated $61.3k in total revenue. This organization has experienced exceptional growth, as over the past 4 years, it has increased revenue by an average of 19.3% each year . All expenses for the organization totaled $147.5k during the year ending 06/2024. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2024
Describe the Organization's Mission:
Part 3 - Line 1
SCIENTIFIC RESEARCH. THE XENOBE RESEARCH INSTITUTE CONDUCTS RESEARCH ON NATURAL AND SYNTHETIC SMALL MOLECULE THERAPEUTICS WITH THE ULTIMATE GOAL OF DISCOVERING AND ULTIMATELY TRANSLATING NEW MATERIALS FOR CLINICAL TRIALS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
NATIONAL INSTITUTES OF HEALTH GRANT R21NS128597. WHILE WELL ESTABLISHED AS CLINICAL TARGETS, THE LACK OF MOLECULAR PROBES TO THE LARGE IMMUNOPHILINS CONTINUES TO INHIBIT OUR ABILITY TO EVALUATE AND DRUG THEM CLINICALLY. THIS PROGRAM EXPLORES THE DEVELOPMENT OF A GENERAL PLATFORM TO DISCOVER PROBES THAT TARGET SPECIFIC DOMAINS WITHIN A NEUROLOGICAL PROTEIN. USING CYCLOPHILIN 40 (CYP40), FK506-BINDING PROTEINS FKBP51 AND FKBP52, OUR TEAM SEEKS TO DEFINE CRITICALLY NEEDED REAGENTS TO UNDERSTAND THE ROLE OF THE `LARGE IMMUNOPHILIN' FAMILY IN NEUROLOGICAL DISEASE. WE BEGAN STUDIES ON OUR RECENTLY FUNDED R21 PROGRAM AND HAVE REPORTED SIGNFICANCE SUCCESS WITHIN OUR INITIAL YEAR OF FUNDING.THE REVENUE GENERATED WILL BE USED FOR THE LATTER HALF OF THE PROGRAM. A TWO YEAR AWARD WAS PROVIDED WITHIN THIS FUNDING PERIOD.THESE FUNDS TO COVER SALARIES, RESEARCH SUPPLIES, INSTRUMENT TIME, AND EQUIPMENT ACCESS TO COMPLETE THESE STUDIES.
GRANT FROM METABOLON. FUNDS WERE PROVIDED TO GUIDE SYNTHESIS OF AN UNKNOWN NATURAL PRODUCT INCLUDING PROVIDING SPECTROSCOPIC SERVICES. FUNDS WERE USED TO SPONSOR LECTURE COSTS AS WELL AS CONDUCT SPECTROSCOPIC SERVICES.
VARIGEN BIOSCIENCES / TERRA BIOWORKS. GRANTED FUNDING WAS PROVIDED TO SUPPORT SMALL MOLECULE ISOLATION AND STRUCTURE ELUCIDATION EFFORTS. THESE FUNDS WERE USED TO COVER RESEARCH SUPPLIES, INSTRUMENT TIME, AND EQUIPMENT ACCESS TO COMPLETE THESE STUDIES. TWO PUBLICATIONS WERE PUBLISHED: PHAM NT, ALVES J, SARGISON FA, CULLUM R, WILDENHAIN J, FENICAL W, BUTLER MS, MEAD DA, DUGGAN BM, FITZGERALD JR, LA CLAIR JJ, AUER M. NANOSCALED DISCOVERY OF A SHUNT RIFAMYCIN FROM SALINISPORA ARENICOLA USING A THREE-COLOR GFP-TAGGED STAPHYLOCOCCUS AUREUS MACROPHAGE INFECTION ASSAY. ACS INFECT DIS. 2023 AUG 11;9(8):1499-1507. STANKEY RJ, JOHNSON D, DUGGAN BM, MEAD DA, LA CLAIR JJ. A SURVEY OF DIDEMNIN DEPSIPEPTIDE PRODUCTION IN TISTRELLA. MAR DRUGS. 2023 JAN 17;21(2):56. DOI: 10.3390/MD21020056.
NATIONAL INSTITUTES OF HEALTH GRANT R01CA236352 VIA A SALK INSTITUTE SUB-AWARD. STUDIES ASSOCIATED WITH SUB-AWARD ASSOCIATED WITH NIH GRANT R01CA236352 WERE CONDUCTED. THESE STUDIES FOCUSED ON DEVELOPING METHODS FOR PLANT NATURAL PRODUCT PRODUCTION, ISOLATION AND STRUCTURE ELUCIDATION. AS WELL AS THE PREPARATION OF PROBES AND SYNTHETIC MATERIALS. THE REMAINING FUNDS ARE BEING USED TO SUPPORT THE ONGOING EFFORTS TOWARDS THIS PROGRAM.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
James J La Clair President | OfficerTrustee | 5 | $44,193 |
Manfred Auer Director | OfficerTrustee | 5 | $0 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $13,500 |
| All other contributions, gifts, grants, and similar amounts not included above | $47,815 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $61,315 |
| Total Program Service Revenue | $0 |
| Investment income | $0 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $61,315 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $44,193 |
| Compensation of current officers, directors, key employees. | $0 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $0 |
| Other employee benefits | $0 |
| Payroll taxes | $20,690 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $0 |
| Fees for services: Accounting | $2,482 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $0 |
| Advertising and promotion | $0 |
| Office expenses | $4,454 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $0 |
| Travel | $10,596 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $11,000 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $0 |
| Insurance | $0 |
| All other expenses | $0 |
| Total functional expenses | $147,500 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $131,426 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $96,675 |
| Prepaid expenses and deferred charges | $0 |
| Net Land, buildings, and equipment | $0 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $228,101 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $0 |
| Total liabilities | $0 |
| Net assets without donor restrictions | $228,101 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $228,101 |